Triple Agonist Peptide
The Triple Agonist Peptide from HG Wellness Peptides is designed for experimental frameworks investigating simultaneous activation of GLP-1, GLP-2, and glucagon/GLP-3-related receptors. This tri-agonist profile makes it relevant for advanced studies of metabolic signaling pathways and intestinal cellular response mechanisms.
Produced in GMP-aligned U.S. facilities via solid-phase synthesis, the peptide is purified to high standards and verified through independent HPLC and mass spectrometry. Each lot includes a unique batch identifier and a detailed Certificate of Analysis, simplifying cross-study comparison and regulatory documentation within laboratory settings.
Delivered as a lyophilized powder, it supports stable storage prior to use in concentration-response studies, receptor profiling, or combinatorial pathway research.
This Triple Agonist Peptide is supplied strictly for Research Use Only and is not intended for human or veterinary administration.
Disclaimer
All products offered by HG Wellness Peptides are strictly intended for laboratory, scientific, and research purposes only. They are NOT for human consumption, clinical use, veterinary application, diagnostic procedures, or direct administration of any kind.
None of the statements on this website have been evaluated or approved by the U.S. Food and Drug Administration (FDA). These products are not medical devices, supplements, or drugs, and are not intended to diagnose, treat, cure, or prevent any disease, condition, or physical ailment.
By purchasing from this website, the buyer acknowledges and agrees that they are at least 21 years of age and are fully qualified, trained, and equipped to handle research chemicals in accordance with applicable laws, health, and safety protocols. HG Wellness Peptides assumes no liability for any direct, indirect, or consequential damages resulting from improper handling, misuse, or unauthorized application of these products.
Reach Out Anytime
Send questions about peptides, orders, or documentation, and our team responds promptly with clear, evidence-based guidance.